Uretron D/s Tablet
NDC 12539-144
Product Information
Uretron D/s (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate) is a UNAPPROVED DRUG OTHER-approved product labeled by Doral Pharmamedics Inc Dba A.g. Marin Pharmaceuticals. This medication is typically used as a increased large intestinal motility [pe]. It is supplied as a blue tablet for oral administration. This product entry covers the primary NDC 12539-144 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
SAT;902
Code Structure Chart
Product Details
What is NDC 12539-144?
What are the uses of this product?
What are Active Ingredients of this product?
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE .12 mg/1
- PHENYL SALICYLATE 81.6 mg/1
- HYOSCYAMINE SULFATE 10.8 mg/1
- METHYLENE BLUE 36.2 mg/1 - A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.
- METHENAMINE 40.8 mg/1 - An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173)
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)
- SODIUM CATION (UNII: LYR4M0NH37) (Active Moiety)
- PHENYL SALICYLATE (UNII: 28A37T47QO)
- PHENYL SALICYLATE (UNII: 28A37T47QO) (Active Moiety)
- HYOSCYAMINE SULFATE (UNII: F2R8V82B84)
- HYOSCYAMINE (UNII: PX44XO846X) (Active Moiety)
- METHYLENE BLUE (UNII: T42P99266K)
- METHYLENE BLUE CATION (UNII: ZMZ79891ZH) (Active Moiety)
- METHENAMINE (UNII: J50OIX95QV)
- METHENAMINE (UNII: J50OIX95QV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)
- CROSPOVIDONE (UNII: 68401960MK)
- ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POLYETHYLENE GLYCOL (UNII: 3WJQ0SDW1A)
- POLYVINYL ALCOHOL (UNII: 532B59J990)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1047786 - hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet
- RxCUI: 1087457 - Uretron D-S 0.12 MG / 81.6 MG / 10.8 MG / 36.2 MG / 40.8 MG Oral Tablet
- RxCUI: 1087457 - hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG Oral Tablet [Uretron DS]
- RxCUI: 1087457 - Uretron D-S (hyoscyamine sulfate 0.12 MG / methenamine 81.6 MG / methylene blue 10.8 MG / phenyl salicylate 36.2 MG / sodium phosphate, monobasic 40.8 MG) Oral Tablet
Which are the Pharmacologic Classes of this product?
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Oxidation-Reduction Activity - [MoA] (Mechanism of Action)
- Oxidation-Reduction Agent - [EPC] (Established Pharmacologic Class)
* Please review the full disclaimer at the bottom of this page.